Stratos Wealth Partners, Ltd. Tricida, Inc. Transaction History

Stratos Wealth Partners, Ltd.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 22, 2022	SELL	$7.31 - $11.85 $826 - $1,339	-113 Reduced 0.65%	17,336 $168,000
Q1 2022 Apr 26, 2022	SELL	$7.35 - $10.63 $7,813 - $11,299	-1,063 Reduced 5.74%	17,449 $143,000
Q4 2021 Jan 14, 2022	SELL	$4.19 - $9.56 $4,190 - $9,560	-1,000 Reduced 5.13%	18,512 $177,000
Q1 2021 Apr 27, 2021	SELL	$4.52 - $7.8 $6,101 - $10,530	-1,350 Reduced 6.47%	19,512 $103,000
Q4 2020 Jan 29, 2021	BUY	$4.37 - $9.46 $2,263 - $4,900	518 Added 2.55%	20,862 $147,000
Q3 2020 Oct 29, 2020	BUY	$8.56 - $26.93 $51,753 - $162,818	6,046 Added 42.29%	20,344 $184,000
Q2 2020 Jul 28, 2020	BUY	$21.21 - $31.55 $424 - $631	20 Added 0.14%	14,298 $393,000
Q1 2020 May 04, 2020	BUY	$18.43 - $38.04 $42,665 - $88,062	2,315 Added 19.35%	14,278 $314,000
Q4 2019 Jan 29, 2020	BUY	$29.6 - $43.71 $11,573 - $17,090	391 Added 3.38%	11,963 $451,000
Q3 2019 Nov 12, 2019	BUY	$29.87 - $42.22 $345,416 - $488,232	11,564 Added 144550.0%	11,572 $357,000
Q3 2019 Nov 12, 2019	SELL	$29.87 - $42.22 $278,716 - $393,954	-9,331 Reduced 99.91%	8 $357,000
Q2 2019 Aug 06, 2019	BUY	$31.16 - $39.46 $291,003 - $368,516	9,339 New	9,339 $369,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Stratos Wealth Partners, Ltd., based on Form 13F filings with the SEC.

Stay updated on Stratos Wealth Partners, Ltd. with notifications on news.